Edible Vaccines

  • Jyoti Saxena
  • Shweta Rawat


In recent years edible vaccine emerged as a new concept developed by biotechnologists. Edible vaccines are subunit vaccines where the selected genes are introduced into the plants and the transgenic plant is then induced to manufacture the encoded protein. Foods under such application include potato, banana, lettuce, corn, soybean, rice, and legumes. They are easy to administer, easy to store and readily acceptable delivery system for different age group patients yet cost effective. Edible vaccines present exciting possibilities for significantly reducing various diseases such as measles, hepatitis B, cholera, diarrhea, etc., mainly in developing countries. However, various technical and regulatory challenges need to overcome in the path of this emerging vaccine technology to make edible vaccine more efficient and applicable. This chapter attempts to discuss key aspects of edible vaccines like host plants, production, mechanism of action, advantages and limitations, applications, and different regulatory issues concerned to edible vaccines.


Human Immunodeficiency Virus Transgenic Plant Human Papilloma Virus Newcastle Disease Virus Rabies Virus 


  1. Arntzen CJ (1997) Edible vaccines. Public Health Rep 112(3):190–197Google Scholar
  2. Chowdhury K, Bagasra O (2007) An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens. Med Hypo 68:22–30CrossRefGoogle Scholar
  3. Das DK (2009) Plant derived edible vaccines. Curr Tren Biotech Pharm 3(2):113–127Google Scholar
  4. Eibl C, Zou Z, Beck A, Kim M, Mullet J, Koop HU (1999) In vivo analysis of plastid psbA, rbcL and rpl32 UTR elements by chloroplast transformation: tobacco plastid gene expression is controlled by modulation of transcript levels and translation efficiency. Plant J 19:333–345PubMedCrossRefGoogle Scholar
  5. Gruissem W, Tonkyn J (1993) Control mechanisms of plastid gene expression. CRC Critical Rev Plant Biol 12:19–55Google Scholar
  6. Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342(6245):76–78PubMedCrossRefGoogle Scholar
  7. Ma JKC, Hein MB (1995) Immunotherapeutic potential of antibodies produced in plants. Trends Biotechnology 13:522–527CrossRefGoogle Scholar
  8. Ma S, Huang Y, Davis A, Yin Z, Mi Q, Menassa R, Brandle JE, Jevnikar AM (2005) Production of biologically active human interleukin-4 in transgenic tomato and potato. Plant Biotechnol J 3(3):309–318PubMedCrossRefGoogle Scholar
  9. Mason HS, Arntzen CJ (1995) Transgenic plants as vaccine production systems. Trends Biotechnol 13:388–392PubMedCrossRefGoogle Scholar
  10. Mason HS, Lam DMK, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 89:11745–11749PubMedCrossRefGoogle Scholar
  11. Mason HS, Haq TA, Clements JD, Arntzen CJ (1998) Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 16:1336–1343PubMedCrossRefGoogle Scholar
  12. Mason HS, Warzecha H, Tsafir MS, Arntzen CJ (2002) Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 8:324–329PubMedCrossRefGoogle Scholar
  13. Mor TS, Gomez Lim MA, Palmer KE (1998) Edible vaccines: a concept comes of age. Trends Microbiol 6:449–453PubMedCrossRefGoogle Scholar
  14. Mor TS, Richter L, Mason HS (1999) Expression of rotavirus proteins in transgenic plants. In: Altman A, Ziv M, Izhar S (eds) Plant biotechnology and in vitro biology in the 21st century. Kluwer Academic publishers, Dordrecht, pp 521–524CrossRefGoogle Scholar
  15. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS (2000) Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 18(11):1167–1171PubMedCrossRefGoogle Scholar
  16. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ (2000) Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 182:302–305PubMedCrossRefGoogle Scholar
  17. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, Goodwin P, Arntzen CJ, Mason HS (2005) Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA 102:3378–3382PubMedCrossRefGoogle Scholar
  18. Wang L, Goschnick MW, Coppel RL (2004) Oral immunization with a combination of Plasmodium yoelii merozoite surface protein 1 and 4/5 enhances protection against lethal malarial challenge. Infect Immunol 72:6172--6175Google Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  1. 1.Biochemical Engineering DepartmentBT Kumaon Institute of TechnologyDwarahatIndia

Personalised recommendations